{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:10:17Z","timestamp":1749701417652,"version":"3.41.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,11]]},"DOI":"10.7759\/cureus.85762","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T12:06:11Z","timestamp":1749643571000},"source":"Crossref","is-referenced-by-count":0,"title":["Aggressive Basal Cell Carcinoma With Rib Metastasis: An Uncommon Presentation of a Common Skin Cancer"],"prefix":"10.7759","author":[{"given":"Junu","family":"Giri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammar","family":"Al Heyasat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandesh","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maida S","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indira","family":"Poojary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.022","article-title":"Advanced basal cell carcinoma: what dermatologists need to know about treatment","volume":"86","author":"Wilson M","year":"2022","unstructured":"Wilson M, Johnson RP, Senft SC, Pan EY, Krakowski AC. Advanced basal cell carcinoma: what dermatologists need to know about treatment. J Am Acad Dermatol. 2022, 86:S14-24. 10.1016\/j.jaad.2022.03.022","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1708701","article-title":"Update on keratinocyte carcinomas","volume":"379","author":"Nehal KS","year":"2018","unstructured":"Nehal KS, Bichakjian CK. Update on keratinocyte carcinomas. N Engl J Med. 2018, 379:363-74. 10.1056\/NEJMra1708701","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0056","article-title":"Basal cell skin cancer, version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schmults CD","year":"2023","unstructured":"Schmults CD, Blitzblau R, Aasi SZ, et al.. Basal cell skin cancer, version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023, 21:1181-203. 10.6004\/jnccn.2023.0056","journal-title":"J Natl Compr Canc Netw"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy412","article-title":"Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics","volume":"29","author":"Nikanjam M","year":"2018","unstructured":"Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R. Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. Ann Oncol. 2018, 29:2192-9. 10.1093\/annonc\/mdy412","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2161517","article-title":"The current clinical approach to difficult-to-treat basal cell carcinomas","volume":"23","author":"Di Brizzi EV","year":"2023","unstructured":"Di Brizzi EV, Argenziano G, Brancaccio G, Scharf C, Ronchi A, Moscarella E. The current clinical approach to difficult-to-treat basal cell carcinomas. Expert Rev Anticancer Ther. 2023, 23:43-56. 10.1080\/14737140.2023.2161517","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0948-9","article-title":"Vismodegib: a review in advanced basal cell carcinoma","volume":"78","author":"Frampton JE","year":"2018","unstructured":"Frampton JE, Basset-S\u00e9guin N. Vismodegib: a review in advanced basal cell carcinoma. Drugs. 2018, 78:1145-56. 10.1007\/s40265-018-0948-9","journal-title":"Drugs"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)70198-1","article-title":"Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial","volume":"16","author":"Basset-Seguin N","year":"2015","unstructured":"Basset-Seguin N, Hauschild A, Grob JJ, et al.. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015, 16:729-736.","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2025.2498999","article-title":"Current treatment options for locally advanced and metastatic basal cell carcinoma. A narrative review","volume":"25","author":"Absil G","year":"2025","unstructured":"Absil G, Rorive A, Marchal N, Piret P, Nikkels AF. Current treatment options for locally advanced and metastatic basal cell carcinoma. A narrative review. Expert Rev Anticancer Ther. 2025, 25:621-32. 10.1080\/14737140.2025.2498999","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.12.009","article-title":"Emerging trends in the treatment of advanced basal cell carcinoma","volume":"64","author":"Migden MR","year":"2018","unstructured":"Migden MR, Chang AL, Dirix L, Stratigos AJ, Lear JT. Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treat Rev. 2018, 64:1-10. 10.1016\/j.ctrv.2017.12.009","journal-title":"Cancer Treat Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.006","article-title":"Guidelines of care for the management of basal cell carcinoma","volume":"78","author":"Kim JY","year":"2018","unstructured":"Kim JY, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018, 78:540-59. 10.1016\/j.jaad.2017.10.006","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000296","article-title":"Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods","volume":"41","author":"Kauvar AN","year":"2015","unstructured":"Kauvar AN, Cronin T Jr, Roenigk R, Hruza G, Bennett R. Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg. 2015, 41:550-71. 10.1097\/DSS.0000000000000296","journal-title":"Dermatol Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.0780","article-title":"Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies","volume":"152","author":"Jacobsen AA","year":"2016","unstructured":"Jacobsen AA, Aldahan AS, Hughes OB, Shah VV, Strasswimmer J. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies. JAMA Dermatol. 2016, 152:816-24. 10.1001\/jamadermatol.2016.0780","journal-title":"JAMA Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18070","article-title":"Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma - real world multicenter cohort study","volume":"36","author":"S\u0142owi\u0144ska M","year":"2022","unstructured":"S\u0142owi\u0144ska M, Dudzisz-\u015aled\u017a M, Sobczuk P, et al.. Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma - real world multicenter cohort study. J Eur Acad Dermatol Venereol. 2022, 36:1219-28. 10.1111\/jdv.18070","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01220-w","article-title":"Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study","volume":"124","author":"Verkouteren BJ","year":"2021","unstructured":"Verkouteren BJ, Wakkee M, Reyners AK, et al.. Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study. Br J Cancer. 2021, 124:1199-206. 10.1038\/s41416-020-01220-w","journal-title":"Br J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14580","article-title":"Known and new facts on basal cell carcinoma","volume":"19","author":"Seidl-Philipp M","year":"2021","unstructured":"Seidl-Philipp M, Frischhut N, H\u00f6llweger N, Schmuth M, Nguyen VA. Known and new facts on basal cell carcinoma. J Dtsch Dermatol Ges. 2021, 19:1021-41. 10.1111\/ddg.14580","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/377265-aggressive-basal-cell-carcinoma-with-rib-metastasis-an-uncommon-presentation-of-a-common-skin-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T12:06:12Z","timestamp":1749643572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/377265-aggressive-basal-cell-carcinoma-with-rib-metastasis-an-uncommon-presentation-of-a-common-skin-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.85762","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}